Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias

Neoplasma

Volumn 43, Issue 6, 1996, Pages 417-419

  Lemez P ^a   Maresova J ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

acute myeloid leukemia; anthracycline induced cardiotoxicity; cardioprotection; cardioxane; ICRF 187

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; RAZOXANE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; FEMALE; HEART PROTECTION; HUMAN; MALE;

EID: 0029987298     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Anonymous: Daunorubicin and the heart. Br. Med. J., 4, 1974, 431-2.
2. BOIRON, M., JACQUILLAT, C., WEIL, M., TANZER, J., LEVY, D., SULTAN, C., BERNARD, J.: Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet, I, 1969, 330-333.
3. BU'LOCK, F.A., GABRIEL, H.M., OAKHILL, A., MOTT, M.G., MARTIN, R.P.: Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J., 70, 1993, 185-188.
4. JURGA, L., MIṠUROVA, E., VANĆIK, J.: Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: A preliminary report. Neoplasma, 40, 1993, 259-262.
5. KONING, J., PALMER, P., FRANKS, C.R., MULDER, D.E., SPEYER, J.L., GREEN, M.D., HELLMANN, K.: Cardioxane- ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat. Rev., 18, 1991, 1-19.
6. LEMEŽ, P.: Significance of lineage specific differentiation markers for complex classification of acute leukemias. Neoplasma, 37, 1990, 253-281.
7. LEMEŽ, P., VÍTEK, A., JELÍNEK, J., LUKÁŠOVÁ, M., PALEČEK, A., SAJDOVÁ, J., JEDLIČKOVÁ, A., VORLOVÁ, Z.: Results of induction therapy of de novo acute myeloid leukemias in the study ÚHKT-911. Vnitř. Lék., 41, 1995, 34-39.
8. LIPP, H.P.: Metabolismus und Toxizität von Zytostatika. 4. Teil: Zytostatikainduzierte Kardio- und Lungentoxizität. Krankenhauspharmazie, 15, 1994, 392-401.
9. MAREŠOVÁ, J., CIESLAR, P., MAREČEK, Z., KLENER, P.: Cardioprotective action of Cardioxane (ICRF-187) in the treatment with antracycline cytostatics and its possible follow-up. Prakt. Lék., 74, 1994, 24-25.
10. SPEYER, J.L., GREEN, M.D., KRAMER. E. et al.: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319, 1988, 745-752.
11. SPEYER, J.L., GREEN, M.D., ZELENIUCH-JACQUOTTE, A. et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10, 1992, 117-127.
12. VON HOFF, D.D., ROZENCWEIG, M., LAYARD, M., SLAVIK, M., MUGGIA, F.M.: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med., 62, 1977, 200-208.